Page 172 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 6b
19. Tout M, Casasnovas O, Meignan M, et al: Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: A Lymphoma Study Association report. Blood. 129:2616-2623, 2017.
20. Tilly H, Gomes da Silva M, Vitolo U, et al: Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26:v116-v125, 2015 (suppl 5).
21. VitoloU,TrněnýM,BeladaD,etal:Obinutuzumaborrituximabpluscyclophosphamide,doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 35:3529-3537, 2017.
22. Davies A, Cummin TE, Barrans S, et al: Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): An open-label, randomised, phase 3 trial. Lancet Oncol. 20:649-662, 2019.
23. Younes A, Sehn LH, Johnson P, et al: Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 37:1285-1295, 2019.
24. Vitolo U, Witzig TE, Gascoyne RD, et al: Robust: First report of phase III randomized study of lenalidomide/R-CHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematol Oncol. 37, 2019 (suppl 2; abstr 005).
25. Chapuy B, Stewart C, Dunford AJ, et al: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 24:679-690, 2018. [Errata: Nat Med. 24:1290-1291, 2018; Nat Med 24:1292, 2018].
26. Schmitz R, Wright GW, Huang DW, et al: Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 378:1396-1407, 2018.
170